Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis

References

• International Diabetes Foundation. Available from: https://www.diabetesatlas.org/en/. Accessed February 23, 2021.
   Google Scholar
• Han S, Hagan DL, Taylor JR, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes. 2008;57(6):1723–1729. doi:10.2337/db07-1472
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C. The future of new drugs for diabetes management. Diabetes Res Clin Pract. 2019;2019:155107785.
   Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–2701. doi:10.2337/dci18-0033
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Series: implications of the recent CVOTs in type 2 diabetes: impact on guidelines: the endocrinologist point of view. Diabetes Res Clin Pract. 2020;2020:159107726.
   Google Scholar
• Consoli A, Czupryniak L, Duarte R, et al. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: expert opinion from a European consensus panel. Diabetes Obes Metab. 2020;22(10):1705–1713. doi:10.1111/dom.14102
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Dalan R. Sodium-glucose cotransporter-2 inhibition in type 2 diabetes mellitus: a review of large-scale cardiovascular outcome studies and possible mechanisms of benefit. Cardiol Rev. 2018;26(6):312–320. doi:10.1097/CRD.0000000000000201
   Web of Science ®Google Scholar
• Norhammar A, Bodegard J, Nystrom T, et al. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: a nationwide observational study. Diabetes Obes Metab. 2019;21(5):1136–1145. doi:10.1111/dom.13627
   PubMed Web of Science ®Google Scholar
• Nystrom T, Bodegard J, Nathanson D, et al. Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):831–841. doi:10.1111/dom.12889
   Web of Science ®Google Scholar
• Wittbrodt E, Chamberlain D, Arnold SV, et al. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry. Diabetes Obes Metab. 2019;21(8):1985–1989. doi:10.1111/dom.13738
   Web of Science ®Google Scholar
• Fadini GP, Zatti G, Consoli A, et al. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): a multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017;27(12):1089–1097. doi:10.1016/j.numecd.2017.08.001
   Web of Science ®Google Scholar
• Fadini GP, Solini A, Manca ML, et al. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: a multicentre retrospective study. Diabetes Obes Metab. 2019;21(2):252–260. doi:10.1111/dom.13508
   PubMed Web of Science ®Google Scholar
• Fadini GP, Tentolouris N, Caballero Mateos I, et al. A multinational real-world study on the clinical characteristics of patients with type 2 diabetes initiating dapagliflozin in Southern Europe. Diabetes Ther. 2020;11(2):423–436. doi:10.1007/s13300-019-00744-6
   Web of Science ®Google Scholar
• Fadini GP, Sciannameo V, Franzetti I, et al. Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: a multicentre retrospective study. Diabetes Obes Metab. 2019;21(8):1886–1894. doi:10.1111/dom.13747
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35. doi:10.1016/S2213-8587(19)30384-5
   PubMed Web of Science ®Google Scholar
• Blonde L, Patel C, Wu B, et al. Real-world comparative effectiveness of canagliflozin versus empagliflozin and dapagliflozin in patients with type 2 diabetes in the United States. Adv Ther. 2021;38(1):594–606. doi:10.1007/s12325-020-01549-x
   PubMed Web of Science ®Google Scholar
• Sriphrapradang C, Thewjitcharoen Y, Buranapin S, et al. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study. Curr Med Res Opin. 2020;36(10):1601–1610. doi:10.1080/03007995.2020.1808454
   PubMed Web of Science ®Google Scholar
• Viswanathan V, Singh KP. Use of dapagliflozin in the management of type 2 diabetes mellitus: a real-world evidence study in Indian patients (FOREFRONT). Diabetes Technol Ther. 2019;21(8):415–422. doi:10.1089/dia.2019.0052
   PubMed Web of Science ®Google Scholar
• Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney Dis. 2016;23(1):19–28. doi:10.1053/j.ackd.2015.08.004
   PubMed Web of Science ®Google Scholar
• Rossing K, Christensen PK, Hovind P, et al. Progression of nephropathy in type 2 diabetic patients. Kidney Int. 2004;66(4):1596–1605. doi:10.1111/j.1523-1755.2004.00925.x
   PubMed Web of Science ®Google Scholar
• Fadini GP, Del Prato S, Avogaro A, et al. Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors. Diabetes Obes Metab. 2022;24(2):177–186. doi:10.1111/dom.14599
   Web of Science ®Google Scholar
• Chaturvedi N, Eastwood S. Prescribing by ethnicity: (im)precision medicine? Diabetes Care. 2020;43(8):1687–1689. doi:10.2337/dci20-0015
   Web of Science ®Google Scholar